DDrare: Database of Drug Development for Rare Diseases

Searched query = "Thrombotic thrombocytopenic purpura", "TTP", "Upshaw-Schulman syndrome", "USS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALX-0081; ARC 1779; ARC1779; ARC1779 Injection; Acetate; Anfibatide; Anti-von Willebrand Factor Nanobody; Anti-von Willebrand Factor Nanobody, Caplacizumab; Anti-von Willebrand Factor Nanobody, INN = Caplacizumab; Apadamtase alfa; Apademtase alfa; BAX930; BAX930 - RECOMBINANT HUMAN ADAMTS13; BAX930 or SHP655; CABLIVI; CAPLACIZUMAB; Cablivi; Caplacizumab; Caplacizumab (ALX-0081); Caplacizumab (an anti-von Willebrand Factor Nanobody ALX-0081); Caplacizumab (an anti-von Willebrand Factor Nanobody); Corticosteroid treatment (Methylprednisolone or prednisolone); Corticosteroids; Cryosupernatant plasma; Cyclosporine; Danazol; Desmopressin; Desmopressin acetate; Dexamethasone; HMED-IdeS; IDEC-C2B8, Ro 45-2294; IdeS; IdeS (0.25 mg/kg); IdeS (0.50 mg/kg); Immunosuppressive treatment (eg, rituximab); MABTHERA; MASP-2 antibody; MabThera; Mabthera; Magnesium; Methylprednisolone; Minirin; OMS721; OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody; Octaplas; Octaplas SD; Octaplas infusion; OctaplasLG®; Octaplas®LG; Octostim; Other: Standard of Care; Plasma exchange (PE); Pooled Plasma (Human), Solvent/Detergent Treated; Prednisolone; Prednisone; Procedure: Plasma exchange; RADAMTS-13; Recombinant A Disintegrin And Metalloproteinase with Thrombospondin Type-1 Motifs 13 (rADAMTS13); Recombinant A Disintegrin and Metalloproteinase Thrombospondin Type-1 Motifs 13; Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1; Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs; Recombinant A Disintegrin and Metalloproteinase with Thrombospondin Type-1 Motifs 13; Recombinant ADAMTS13; Rituximab; Romiplostim; SHP 655 (BAX 930); SHP655; Standard Plasma; Standard of care; Standrd of Care treatment; Sulfate; Sulfate, Magnesium; TAK-755 orBAX930 or SHP655; Uniplas; Von willebrand factor

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01754545 (ClinicalTrials.gov)	September 2012	12/12/2012	Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura	Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura	Purpura, Thrombotic Thrombocytopenic	Drug: Octaplas infusion and placebo (group 1);Drug: Octaplas infusion and placebo (group 2)	St. Olavs Hospital	Norwegian University of Science and Technology	Withdrawn	18 Years	65 Years	Both	0	Phase 4	Norway

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01754545
(ClinicalTrials.gov)

September 2012

12/12/2012

Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura

Purpura, Thrombotic Thrombocytopenic

Drug: Octaplas infusion and placebo (group 1);Drug: Octaplas infusion and placebo (group 2)

St. Olavs Hospital

Norwegian University of Science and Technology

Withdrawn

18 Years

65 Years

Both

Phase 4

Norway